Lung cancer is the leading cause of cancer-related death in the United States, accounting for over 30% of cancer deaths in men and 25% in women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are uniformly aggressive tumors, with rates of regional or distant metastases at diagnosis as high as 70%. Because the majority of these tumors are unresectable, patients with relatively good performance status receive platinum-based chemotherapy. Although no treatment consensus exists, currently recommended regimens for SCLC include PE (cisplatin and etoposide), CAV (cyclophosphamide, doxorubicin, and vincristine), CAE (cyclophosphamide, doxorubicin, and etoposide), and CAVE (cyclophosphamide, doxorubicin, vincristine, and etoposide). Of these, the PE regimen has been widely accepted in the United States, although CE (carboplatin and etoposide) provides better tolerability. For NSCLC, standard chemotherapy regimens have included platinum-based therapy (cisplatin and a vinca alkaloid or PE). Data from recent studies suggest that the addition of paclitaxel to platinum modestly improves tumor response and survival in NSCLC. Although SCLC and NSCLC are both responsive to first-line chemotherapy, most patients relapse and die from their disease, with 5-year survival rates of approximately 15%. Given the disappointing survival rates associated with SCLC and NSCLC, the introduction of new cytotoxic agents has been eagerly anticipated. Evidence of improved response and extended survival is mounting for various combinations of established regimens (e.g., PE) with newer drugs exhibiting novel mechanisms of action and single-agent antitumor activity, such as gemcitabine, paclitaxel, docetaxel, vinorelbine, and topotecan. This article reviews the current standards of care in SCLC and NSCLC, and introduces the potential role of newer agents given in combination with standard chemotherapy.

1.
Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999;49:33–64.
2.
Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001;51:15–36.
3.
World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment: Geneva, Switzerland, World Health Organization, 1979.
4.
Gloeckler Ries LA, Hankey BF, Miller BA, Hartman AM, Edwards BK: Cancer Statistics Review, 1973–1988. Bethesda, National Institutes of Health, 1991, pp VI21.
5.
Strauss GM, Gleason RE, Sugarbaker DJ: Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening. Chest 1995;107(suppl):270–279.
6.
Strauss GM, Gleason RE, Sugarbaker DJ: Screening for lung cancer. Another look; a different view. Chest 1997;111:754–768.
7.
Pirozynski M: Bronchoalveolar lavage in the diagnosis of peripheral, primary lung cancer. Chest 1992;102:372–374.
8.
Langer CJ: The role of new agents in advanced non-small-cell lung carcinoma. Curr Oncol Rep 2000;2:76–89.
9.
Green MR, Rocha Lima CM, Sherman CA: Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol 2000;10:289–295.
10.
Johnson DH: Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: A historical perspective and the Eastern Cooperative Oncology Group experience. Chest 2000;117(suppl 1):133–137.
11.
Zochbauer-Muller S, Pirker R, Huber H: Treatment of small cell lung cancer patients. Ann Oncol 1999;10(suppl 6):83–91.
12.
De Ruysscher D, Vansteenkiste J: Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 2000;55:1–9.
13.
Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J: NCCN small-cell lung cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(suppl):179–194.
14.
Ettinger DS, Cox JD, Ginsberg RJ, Komaki R, Kris MG, Livingston RB, Sugarbaker DJ: NCCN non-small-cell lung cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(suppl):81–111.
15.
Bunn PA, Kelly K: New combinations in the treatment of lung cancer: A time for optimism. Chest 2000;117(suppl 1):138–143.
16.
Kelly K: New chemotherapy agents for small cell lung cancer. Chest 2000;117(suppl 1):156–162.
17.
Montazeri A, Gillis CR, McEwen J: Quality of life in patients with lung cancer: A review of literature from 1970 to 1995. Chest 1998;113:467–481.
18.
Ginsberg RJ, Vokes EE, Rosenzweig K: Non-small cell lung cancer; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2001, vol 1, pp 925–951.
19.
Murren J, Glatstein E, Pass HI: Small cell lung cancer; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2001, vol 1, pp 983–1018.
20.
Seifter EJ: Small cell lung cancer: A distinct clinicopathologic entity; in Bitran JD, Golomb HM, Little AG (eds): Lung Cancer: A Comprehensive Treatise. Orlando, Grune & Stratton, 1988, pp 285–300.
21.
Pujol JL, Daures JP, Riviere A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarie E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T: Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300–308.
22.
Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282–291.
23.
Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, Brechot JM, Lebeau B: The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. ‘Petites Cellules’ Group. Cancer 1999;86:2238–2245.
24.
Sekido Y, Fong KM, Minna JD: Molecular biology of lung cancer; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2001, vol 1, pp 917–925.
25.
Greco FA, Hainsworth JD: Practical approaches to the treatment of patients with extensive stage small cell lung cancer. Semin Oncol 1994;21:3–6.
26.
Ihde DC: Staging evaluation and prognostic factors in small cell lung cancer; in Aisner J (ed): Lung Cancer. New York, Churchill Livingstone, 1985, pp 241–268.
27.
Beahrs OH (ed): Manual for Staging of Cancer/American Joint Committee on Cancer, ed 4. Philadelphia, Lippincott, 1992.
28.
Ihde DC: Chemotherapy of lung cancer. N Engl J Med 1992;327:1434–1441.
29.
Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996–3018.
30.
Brigham BA, Bunn PA Jr , Minna JD, Cohen MH, Ihde DC, Shackney SE: Growth rates of small cell bronchogenic carcinomas. Cancer 1978;42:2880–2886.
31.
Abrams J, Doyle LA, Aisner J: Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988;15:261–277.
32.
Sculier JP, Feld R, Evans WK, DeBoer G, Shepherd FA, Payne DG, Pringle JF, Yeoh JL, Quirt IC, Curtis JE, Myers R, Herman JG: Neurologic disorders in patients with small cell lung cancer. Cancer 1987;60:2275–2283.
33.
Matthews MJ, Kanhouwa S, Pickren J, Robinette D: Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 3 1973;4:63–67.
34.
Ihde DC, Pass HI, Glatstein EJ: Small cell lung cancer; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, ed 4. Philadelphia, Lippincott, 1993, pp 723–758.
35.
Takada M, Fukuoka M, Furuse K, Ariyoshi Y, Ikegami H, Kurita Y, Nishiwaki Y, Nishikawa H, Watanabe K, Noda K, Saijo N, for the JCOG-Lung Cancer Study Group: Phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) for limited-stage (LS) small cell lung cancer (SCLC): Preliminary results of the Japan Clinical Oncology Group (JCOG) [abstract]. Proc Am Soc Clin Oncol 1996;15:372 (abstract 1103).
36.
Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D, for the Hellenic Cooperative Oncology Group for Lung Cancer Trials: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study. Semin Oncol 1994;21(suppl 6):23–30.
37.
Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 1997;15:893–900.
38.
Turrisi AT III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–271.
39.
Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, Sadura A, Feld R, Levitt M, Weirzbicki R, Ayoub J, Maroun JA, Wilson KS, for the National Cancer Institute of Canada Clinical Trials Group: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336–344.
40.
Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, Mornet M, Coetmeur D, Lebeau B, ‘Petites Cellules’ Group: Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. Lung Cancer 1999;25:105–113.
41.
Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348:563–566.
42.
Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 – a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114–2122.
43.
Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8–15.
44.
Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, Shepherd FA, Clark DA, Levitt M, MacDonald A: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987;107:451–458.
45.
Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855–861.
46.
Feld R, Evans WK, Coy P, Hodson I, MacDonald AS, Osoba D, Payne D, Shelley W, Pater JL: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987;5:1401–1409.
47.
Bunn PA, Carney DN: Overview of chemotherapy for small cell lung cancer. Semin Oncol 1997;24(suppl 7):69–74.
48.
Samantas E, Skarlos DV, Pectasides D, Nicolaides P, Kalofonos H, Mylonakis N, Vardoulakis Th, Kosmidis P, Pavlidis N, Fountzilas G: Combination chemotherapy with low doses of weekly carboplatin and oral etoposide in poor risk small cell lung cancer. Lung Cancer 1999;23:159–168.
49.
Hainsworth JD, Greco FA: The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1999;26(suppl 2):60–66.
50.
Greco FA, Hainsworth JD: Paclitaxel-based therapy in non-small-cell lung cancer: Improved third generation chemotherapy. Ann Oncol 1999;10(suppl 5):63–67.
51.
Belani CP: Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest 2000;117(suppl 1):144–151.
52.
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998;16:2459–2465.
53.
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Laufman LR, Baker LH, Fisher RI, Bearman SI, Taylor SA, Livingston RB: Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308) [abstract]. Proc Am Soc Clin Oncol 1996;15:374 (abstract 1110).
54.
Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360–367.
55.
Rocha Lima CMS, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR: Single-agent gemcitabine and gemcitabine/irinotecan combination (IrimoGem) in non-small cell lung cancer. Semin Oncol 1999;26(suppl 16):43–50; discussion 71–72.
56.
von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743–1749.
57.
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658–667.
58.
Fukuoka M, Masuda N, Kudoh S, Negoro S: Irinotecan in small-cell lung cancer – Japanese trials. Oncology (Huntingt) 2000;14(suppl 5):57–62.
59.
Lynch TJ Jr, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E III: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:347–352.
60.
Kindler HL, Kris MG, Smith IE, Miller VA, Grant SC, Krebs JB, Ross GA, Slevin ML: Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol 1998;21:438–441.
61.
Weitz JJ, Marschke RF Jr, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL: A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000;28:157–162.
62.
White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M: Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 2000;6:868–873.
63.
Ginsberg RJ, Vokes EE, Raben A: Non-small cell lung cancer; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 858–911.
64.
Scagliotti GV, Novello S, Selvaggi G: Multidrug resistance in non-small-cell lung cancer. Ann Oncol 1999;10(suppl 5):83–86.
65.
Ihde DC, Minna JD: Non-small cell lung cancer. II. Treatment. Curr Probl Cancer 1991;15:105–154.
66.
Friedel G, Hruska D, Budach W, Wolf M, Kyriss T, Hurtgen M, Eulenbruch HP, Dierkesmann R, Toomes H: Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. Lung Cancer 2000;30:175–185.
67.
Investigation for mediastinal disease in patients with apparently operable lung cancer. Canadian Lung Oncology Group. Ann Thorac Surg 1995;60:1382–1389.
68.
Patterson GA, Ginsberg RJ, Poon PY, Cooper JD, Goldberg M, Jones D, Pearson FG, Todd TR, Waters P, Bull S: A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 1987;94:679–684.
69.
Michel F, Soler M, Imhof E, Perruchoud AP: Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991;46:469–473.
70.
Mintz BJ, Tuhrim S, Alexander S, Yang WC, Shanzer S: Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest 1984;86:850–853.
71.
Butler AR, Leo JS, Lin JP, Boyd AD, Kricheff II: The value of routine cranial computed tomography in neurologically intact patients with primary carcinoma of the lung. Radiology 1979;131:399–401.
72.
Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G: Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 1995;108:1264–1271.
73.
Silvestri GA, Littenberg B, Colice GL: The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med 1995;152:225–230.
74.
Nielsen ME Jr, Heaston DK, Dunnick NR, Korobkin M: Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma. AJR Am J Roentgenol 1982;139:317–320.
75.
Oliver TW Jr, Bernardino ME, Miller JI, Mansour K, Greene D, Davis WA: Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984;153:217–218.
76.
Ettinghausen SE, Burt ME: Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol 1991;9:1462–1466.
77.
Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899–909.
78.
Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210–1215.
79.
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, Green MR: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940–945.
80.
Perng RP, Chen YM, Ming-Liu J, Tsai CM, Lin WC, Yang KY, Whang-Peng J: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15:2097–2102.
81.
Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W: Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997;8:525–529.
82.
Altavilla G, Adamo V, Buemi B, Marabello G, Maisano R, Lupo G, Bene A, Bellocco G: Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer. Anticancer Res 2000;20:3675–3678.
83.
Gridelli C: The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001;6(suppl 1):4–7.
84.
Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145–157.
85.
Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074–1080.
86.
Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866–1872.
87.
Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP: Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 1993;342:19–21.
88.
Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623–631.
89.
Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A, Rosell R: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12–18.
90.
Belani CP, Natale RB, Lee JS, Socinski M, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Sridhar K: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1998;17:455a (abstract 1751).
91.
Gatzemeier U, von Pawel J, Gottfried M, ten Velde GPM, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:3390–3399.
92.
Giaccone G, Splinter TAW, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MCSG, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE, for the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998;16:2133–2141.
93.
Langer CJ, Leighton JC, Comis RL, O’Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860–1870.
94.
Schiller JH, Harrington D, Sandler A, Belani C, Langer C, Krook J, Johnson DH: A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000;19:1a (abstract 2).
95.
Georgoulias V, Papadakis E, Alexopoulos A, Stavrinidis E, Bania E, Rapti A, Grigoratou T, Kouroussis C, Kakolyris S, Samonis G: Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial [abstract]. Proc Am Soc Clin Oncol 1999;18:461a (abstract 1778).
96.
Kelly K, Crowley J, Bunn PA, Livingston RB, Gandara DR: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1999;18:461a (abstract 1777).
97.
Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997;15:297–303.
98.
Sandler AB, Nemunaitis J, Denham Ch, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold Ch, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122–130.
99.
Le Chevalier T, Brisgand D, Soria JC, Douillard JY, Pujol JL, Ruffie P, Aberola V, Cigolari S: Long-term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001;6(suppl 1): 8–11.
100.
Scagliotti GV, Crino L, Pozzi E, Corgna E, Selvaggi G, Novello S, Salsano G, Gentile A, Palladino M, Marracolo F, Tonato M: Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer. Lung Cancer 1999;25:39–46.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.